Wells Fargo stock edges higher as WFC nears earnings after soft U.S. jobs data

Wells Fargo stock edges higher as WFC nears earnings after soft U.S. jobs data

New York, January 9, 2026, 15:25 EST — Regular session

  • Wells Fargo shares were little changed in afternoon trade, with big-bank peers mixed.
  • Investors are positioning for U.S. bank earnings next week, with Wells Fargo due Jan. 14.
  • A cooler-than-expected U.S. jobs report nudged yields and rate bets, a key input for bank margins.

Wells Fargo & Company shares were up 0.2% at $95.78 in afternoon trade on Friday. JPMorgan was flat, while Bank of America slipped and Citigroup gained.

The stock has steadied as traders turn to bank earnings next week, with JPMorgan Chase due Jan. 13 and Wells Fargo, Bank of America and Citigroup set for Jan. 14. Analysts expect Wells Fargo’s fourth-quarter earnings per share to rise 17.5% from a year earlier, helped by net interest income (NII) — what a bank earns on loans minus what it pays out on deposits — and stronger investment banking; Argus Research analyst Stephen Biggar called the quarter a “perfect recipe” for investment-banking revenues. Investors are also watching the bank’s growth plans after regulators lifted its $1.95 trillion asset cap in 2025. (Reuters)

Friday’s U.S. jobs report fed into that setup. Employers added 50,000 jobs in December, below forecasts for 60,000, and the unemployment rate eased to 4.4%, Reuters reported, with the 10-year Treasury yield last down slightly at 4.171%. Tim Ghriskey, senior portfolio strategist at Ingalls & Snyder, said payrolls were “a little bit light” but still “fairly strong.” (Reuters)

Wells Fargo said it will publish fourth-quarter 2025 results at about 7:00 a.m. Eastern on Jan. 14 and host a conference call at 10:00 a.m. that day. (Wells Fargo Newsroom)

Wells Fargo closed up 1.39% on Thursday at $95.60, after falling 2.18% a day earlier. Thursday’s finish left it about 2.2% below its 52-week high of $97.76 set on Jan. 5, MarketWatch data showed. (MarketWatch)

In the earnings call, investors are likely to press management on deposit costs, loan growth and how quickly investment-banking fees translate into profits. They will also parse the outlook for net interest margin, the spread between interest income and interest expense, with bond yields still doing most of the day-to-day work.

But the setup cuts both ways. A bigger drop in yields can pinch interest income, while hotter inflation or a policy shock can keep rates high and chill dealmaking, leaving banks with less advisory and trading momentum than the market is leaning on.

Wells Fargo reports before the bell on Jan. 14, with the conference call set for 10 a.m. Eastern. Traders will look for updates on NII, expenses and fee growth — and any shift in the bank’s tone on 2026.

Stock Market Today

  • Vera Therapeutics Valuation Under Scrutiny After Momentum
    January 10, 2026, 5:06 PM EST. Vera Therapeutics (VERA) trades at $48.71 after a sharp rally, with a 1-month gain near 9.9% and a 3-month advance around 61.9% as investors weigh growth against clinical and financing risks. The 3-year total shareholder return runs about 7x. On a P/B of 8.7x, the stock sits above the broader US biotech average (2.7x) but below some peers (11.8x). A DCF view yields a fair value about $242.41, implying roughly an 80% discount to the current price. The company reports no revenue and a net loss of about $251.9 million. Upside depends on trial progress and funding; downside risk remains if milestones slip or financing deteriorates. Analysts' targets are higher than today's price, keeping a watchful eye on progress.
Why Equity Residential stock is sliding today: BMO downgrade meets a $400 million asset sale
Previous Story

Why Equity Residential stock is sliding today: BMO downgrade meets a $400 million asset sale

Deckers Outdoor stock drops as Needham pulls DECK from Conviction List, putting Hoka growth back under a microscope
Next Story

Deckers Outdoor stock drops as Needham pulls DECK from Conviction List, putting Hoka growth back under a microscope

Go toTop